Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 05, 2015 07:30 ET | Source: Minerva Neurosciences, Inc

Minerva Neurosciences Reports Second Quarter 2015 Financial Results and Business Updates

Opening of clinical sites in six countries builds momentum in MIN-101 Phase IIb schizophrenia trial First patient dosed in Phase IIa study with MIN-117 in major depressive disorder First patient...
July 29, 2015 08:00 ET | Source: Minerva Neurosciences, Inc

Minerva Neurosciences to Report Second Quarter 2015 Financial Results and Host Conference Call on August 5, 2015

WALTHAM, Mass., July 29, 2015 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat...
June 16, 2015 07:30 ET | Source: Minerva Neurosciences, Inc

Minerva Neurosciences Provides Update on MIN-202, Selective Orexin-2 Receptor Antagonist

Data in Insomnia Presented by Janssen at SLEEP 2015 IND Now in Effect to Expand Clinical Testing into Adjunctive Major Depressive Disorder WALTHAM, Mass., June 16, 2015 (GLOBE NEWSWIRE) --...
May 28, 2015 08:00 ET | Source: Minerva Neurosciences, Inc

Minerva Neurosciences to Present at Upcoming Investor Conferences in June

WALTHAM, Mass., May 28, 2015 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq:NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat...
May 18, 2015 07:30 ET | Source: Minerva Neurosciences, Inc

Minerva Neurosciences Announces Appointment of Dr. Fouzia Laghrissi-Thode to Its Board of Directors

WALTHAM, Mass., May 18, 2015 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq:NERV) today announced the appointment of Fouzia Laghrissi-Thode, M.D. to its board of directors, effective...
May 07, 2015 08:00 ET | Source: Minerva Neurosciences, Inc

Minerva Neurosciences Reports First Quarter 2015 Financial Results and Other Key Business Updates

MIN-101 Phase 2b trial for schizophrenia on track with enrollment underway; new regulatory approvals to conduct trials in Europe MIN-117 Phase 2a study in Major Depressive Disorder (MDD) on track...
April 30, 2015 08:00 ET | Source: Minerva Neurosciences, Inc

Minerva Neurosciences to Host First Quarter 2015 Financial Results Webcast and Conference Call

WALTHAM, Mass., April 30, 2015 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq:NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat...
March 26, 2015 16:01 ET | Source: Minerva Neurosciences, Inc

Minerva Neurosciences Reports Fourth Quarter and Full Year 2014 Financial Results

- MIN-101 Phase 2b trial for schizophrenia on track - - Phase 2a trial planned for MIN-202 in primary insomnia in mid-2015; Phase 1b in MDD patients also expected to begin in mid-2015 - -...
March 19, 2015 17:39 ET | Source: Minerva Neurosciences, Inc

Minerva Neurosciences to Host Fourth Quarter and Full Year 2014 Financial Results Webcast and Conference Call

WALTHAM, Mass., March 19, 2015 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq:NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat...
March 18, 2015 16:05 ET | Source: Minerva Neurosciences, Inc

Minerva Neurosciences Completes Private Placement, Raises $31 Million

WALTHAM, Mass., March 18, 2015 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq:NERV) today announced that it has closed the private placement announced on March 13, 2015. Investors in the...